Pfizer CEO Discusses Q1 Results, Pipeline

Pfizer CEO Albert Bourla discusses the company's strong first quarter results, driven by execution and a robust pipeline, particularly in cancer and obesity treatments. He highlights the company's focus on enhancing its pipeline, investing in AI, and managing costs while investing in R&D. He also shares his perspective on the FDA's approach to approving new medicines.